Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00158210 · ClinicalTrials.gov registry record · Phase 1
Rivastigmine For Methamphetamine Dependent Individuals
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00158210 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 18 participants.
The verdict
NCT00158210, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Methamphetamine abuse has been steadily increasing over the past decade. Rivastigmine is a medication that may be helpful in treating methamphetamine dependence. The purpose of this study is to evaluate the effectiveness of rivastigmine in treating methamphetamine dependent individuals.
Interventions
- DRUG Rivastigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00158210
The ClinicalTrials.gov registry entry for NCT00158210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rivastigmine is the first listed.
NCT00158210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00158210 about?
NCT00158210 is a clinical study titled "Rivastigmine For Methamphetamine Dependent Individuals". Methamphetamine abuse has been steadily increasing over the past decade. Rivastigmine is a medication that may be helpful in treating methamphetamine dependence. The purpose of this study is to evaluate the effectiveness of rivastigmine in treating methamphetamine dependent individuals.
What is the current status of trial NCT00158210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-05. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00158210?
The interventions under investigation include: Rivastigmine (DRUG).
Who is sponsoring clinical trial NCT00158210?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.